Clinical trials: Prostate Cancer, suspended
Prostate Cancer, Prostate Neoplasm
Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient
The diagnostic tools for detecting patients with early prostate cancer are limited due to poor diagnostic performance. The positron emission tomography (PET) combination with the diagnostic radiopharmacy is a non-invasive tool to…
- Trial name
- NCT05422105
- Testing
- 18F-PSMA-1007
- Where
- 2 sites in Taiwan
- Volunteers
- 230 people
- Sponsor
- Primo Biotechnology Co., Ltd
Prostate Cancer
Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation
A multicentre observational study on treatment approaches and biomarkers in de novo metastatic hormone sensitive prostate cancer in Russian Federation
- Trial name
- PRIME (NCT07146113)
- Where
- 16 sites in Russia
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Prostatic Neoplasm
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
This study will evaluate an experimental drug called EZN-4176 to determine the anticancer effects when it is given to patients with an advanced form of prostate cancer called castration-resistant prostate cancer (CRPC).
- Trial name
- NCT01337518
- Testing
- EZN-4176
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
Metastatic Castrate Resistant Prostate Cancer
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
Demonstrate detection of ARv7 splice variant transcripts from exosomes in the circulation of MCRPC patients pre and post treatment with selective Androgen pathway inhibitors (i.e. abiraterone and enzalutamide)
- Trial name
- NCT03236688
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
Prostate Cancer, Prostate Cancer Metastatic
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
This is a phase 2, multicenter, open-label study to evaluate the efficacy of abivertinib with abiraterone in patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT05361915
- Testing
- Abivertinib, Abiraterone
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Sorrento Therapeutics, Inc.
Cancer
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or…
- Trial name
- NCT01604863
- Testing
- HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Solid Tumor
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.
- Trial name
- NCT03970382
- Testing
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- PACT Pharma, Inc.
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Neoplasms
A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors
5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD.
- Trial name
- NCT00264472
- Testing
- ADH300004
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Adherex Technologies, Inc.
Prostate Cancer
The Plenaxis® Experience Study
Praecis is currently conducting a 2000 patient Experience Study; this is a Phase IV commitment postmarketing safety study in the Food and Drug Administration (FDA) indicated population of patients receiving Plenaxis®.
- Trial name
- NCT00103623
- Testing
- Plenaxis
- Where
- 60 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- PRAECIS Pharmaceuticals Inc.
Castrate-Resistant Prostate Cancer
LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer
This is a single center, single arm Phase I study to establish the safety and efficacy of intravenously administered lentivirally transduced LIGHT-PSMA-specific CAR modified autologous T cells (PSMA-CART cells) in patients with…
- Trial name
- NCT04053062
- Testing
- LIGHT-PSMA-CART cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Bioray Laboratories
Prostate Cancer
ClariCore System Used in Transperineal Prostate Biopsy
The overall objective of this study is to acquire ultrasound images, spectral data and prostate tissue biopsy cores using the ClariCore System via a transperineal approach.
- Trial name
- NCT03734575
- Testing
- ClariCore System
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Precision Biopsy, Inc.
Breast Cancer, Glioma
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast…
- Conditions
- Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00909558
- Testing
- Autologous Natural Killer / Natural Killer T Cell Immunotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Envita Medical Center, Inc.